Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly delayed-release versus daily immediate-release risedronate in postmenopausal osteoporosis
2007-001521-98Phase 3Completed
- Sponsor
- Procter & Gamble
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of risedronate in postmenopausal osteoporosis (3 arms), sponsored by Procter & Gamble. Primary endpoint: Percent change from baseline in lumbar spine bone mineral density at Week 52. Started Sep 2007; status: completed.
02
Drugs
risedronate
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on 2007-001521-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001521-98.